Headquartered in Watertown, MA Fiscal year ends December NASDAQ: KYMR kymeratx.com
Kymera Therapeutics is a clinical-stage biopharmaceutical company pioneering the field of targeted protein degradation (TPD) to develop a new class of oral small molecule degrader medicines. The company focuses on immunological diseases, addressing disease targets and pathways that are inaccessible with conventional therapeutics. Its pipeline includes KT-621, a first-in-class oral STAT6 degrader in Phase 2 development for atopic dermatitis and asthma targeting Type 2 inflammation; KT-579, a first-in-class oral IRF5 degrader in Phase 1 for autoimmune diseases including lupus and inflammatory bowel disease; and partnered programs including KT-485 (IRAK4 degrader, partnered with Sanofi) and KT-200 (CDK2 degrader, licensed to Gilead Sciences for oncology). Founded in 2016, the company trades on NASDAQ under the ticker KYMR. Updated
Wall Street analysts reshuffled their bets on Thursday as geopolitical fires, a Fed dissent surprise, and a brutal semiconductor selloff forced some major rating reversals across insurance, gaming, tech, and energy stocks.
Pre-Market Stock Futures: Futures are trading higher on Wednesday as news of an impending end to the Iran war is sending oil prices dramatically lower. This news comes after a bounce-back Tuesday…
Oncology M&A activity is accelerating as large pharmaceutical companies race to replenish pipelines facing patent cliffs and seek exposure to next-generation therapeutic platforms. Five biotechs stand out as compelling acquisition candidates, each…
Kymera Therapeutics (NASDAQ:KYMR) CEO Nello Mainolfi had one line on the February 26, 2026 earnings call that deserves attention beyond the headline numbers: his company just put the first IRF5-directed therapy in…
Kodiak Sciences, Medline, and W.R. Berkley have seen some huge insider purchases, and there were some other notable insider purchases as well..
Secondary offerings from biotechs Immunovant, Kymera Therapeutics, and Wave Life Sciences prompted some huge insider buying recently.
Pre-Market Stock Futures: The futures are trading modestly higher as Thanksgiving Eve has finally arrived. After a slow start on Tuesday, all the major indices began to rally by noon and finished…
Kymera Therapeutics is a clinical-stage biopharmaceutical company pioneering the field of targeted protein degradation (TPD) to develop a new class of oral small molecule degrader medicines.
The Wall Street consensus 12-month price target for KYMR is $139.32.
